| Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data C Fustero-Torre, MJ Jiménez-Santos, S García-Martín, C Carretero-Puche, ... Genome Medicine 13 (1), 187, 2021 | 43 | 2021 |
| Substitution rates predicted by stability-constrained models of protein evolution are not consistent with empirical data MJ Jimenez, M Arenas, U Bastolla Molecular Biology and Evolution 35 (3), 743-755, 2018 | 24 | 2018 |
| Influence of mutation bias and hydrophobicity on the substitution rates and sequence entropies of protein evolution MJ Jiménez-Santos, M Arenas, U Bastolla PeerJ 6, e5549, 2018 | 15 | 2018 |
| Bioinformatics roadmap for therapy selection in cancer genomics MJ Jiménez‐Santos, S García‐Martín, C Fustero‐Torre, T Di Domenico, ... Molecular Oncology 16 (21), 3881-3908, 2022 | 13 | 2022 |
| Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs JS Jutzi, AE Marneth, M Ciboddo, A Guerra-Moreno, MJ Jiménez-Santos, ... Blood, The Journal of the American Society of Hematology 140 (11), 1291-1304, 2022 | 12 | 2022 |
| bollito: a flexible pipeline for comprehensive single-cell RNA-seq analyses L García-Jimeno, C Fustero-Torre, MJ Jiménez-Santos, G Gómez-López, ... Bioinformatics 38 (4), 1155-1156, 2022 | 8 | 2022 |
| CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response JS Jutzi, AE Marneth, MJ Jiménez-Santos, J Hem, A Guerra-Moreno, ... Leukemia 37 (2), 359-369, 2023 | 7 | 2023 |
| In silico drug prescription for targeting cancer patient heterogeneity and prediction of clinical outcome E Piñeiro-Yáñez, MJ Jiménez-Santos, G Gómez-López, F Al-Shahrour Cancers 11 (9), 1361, 2019 | 7 | 2019 |
| PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data MJ Jiménez-Santos, A Nogueira-Rodríguez, E Piñeiro-Yáñez, ... Nucleic Acids Research 51 (W1), W411-W418, 2023 | 6 | 2023 |
| RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer M Ciscar, EM Trinidad, G Perez‐Chacon, M Alsaleem, M Jimenez, ... EMBO Molecular Medicine 15 (4), e16715, 2023 | 3 | 2023 |
| S191: CALRETICULIN-MUTATED HEMATOPOIETIC CELLS ARE VULNERABLE TO THE COMBINED INHIBITION OF THE PROTEASOME AND THE IRE1A-XBP1 AXIS OF THE UNFOLDED PROTEIN RESPONSE JS Jutzi, AE Marneth, MJ Jimenez-Santos, A Guerra-Moreno, SA Myers, ... HemaSphere 6, 92-93, 2022 | 1 | 2022 |
| RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts M Ciscar, EM Trinidad, H Perez-Montoyo, M Alsaleem, ... bioRxiv, 2021.12. 13.470911, 2021 | 1 | 2021 |
| Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq C Fustero-Torre, MJ Jiménez-Santos, S García-Martín, C Carretero-Puche, ... BioRxiv, 2021.04. 08.438954, 2021 | 1 | 2021 |
| Spatial Transcriptomics in Breast Cancer Reveals Tumour Microenvironment-Driven Drug Responses and Clonal Therapeutic Heterogeneity MJ Jiménez-Santos, S García-Martín, M Rubio-Fernández, ... bioRxiv, 2024.02. 18.580660, 2024 | | 2024 |
